39 results
8-K
EX-99.1
TSVT
2seventy bio Inc
5 Apr 24
Regulation FD Disclosure
9:22am
improvement in overall response rates (p<0.0001) with the majority (71%) of patients treated with Abecma achieving a response, and 39% achieving
8-K
EX-99.1
9keotn 5juz
30 Jan 24
2seventy bio Announces New Strategic Path Forward
7:48am
8-K
EX-99.1
tlk3phwi dba28jsyb
12 Dec 23
Regulation FD Disclosure
7:25am
8-K
EX-99.1
z6frq3c k3
13 Sep 23
Unleash Time 2seventy bio company presentation September 2023
4:03pm
8-K
EX-99.1
q2a42usigem
14 Jun 23
Unleash Time 2seventy bio company presentation June 2023
7:02am
PRE 14A
67w80 ja35qo0iwi
18 Apr 23
Preliminary proxy
5:21pm
424B5
5wnc166u
18 Nov 22
Prospectus supplement for primary offering
4:31pm
S-3
ix1wdg6cn0cl1s
7 Nov 22
Shelf registration
4:28pm
S-3
EX-4.6
qete0 tkple76nu1
7 Nov 22
Shelf registration
4:28pm
S-3
EX-4.5
is46dmm4xjqr0k8nx75
7 Nov 22
Shelf registration
4:28pm
POS AM
ibrxa hvl
1 Nov 22
Prospectus update (post-effective amendment)
5:10pm
424B3
ctph8q
6 May 22
Prospectus supplement
4:18pm
S-1
r2a7vkxdhjfnb
28 Apr 22
IPO registration
5:03pm
DEF 14A
a1n9 rcyt992e0z5
26 Apr 22
Definitive proxy
4:11pm
10-K
EX-4.4
4ai3vnuw0klsy3d9tuj4
22 Mar 22
Annual report
7:09am